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Abstract 
Review on POLE, with data on DNA, on the protein 
encoded, and where the gene is implicated. 
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Identity 
Other names: POLE1 
HGNC (Hugo): POLE 
Location: 12q24.33 
Local order: 132,623,762-132,687,359 
DNA/RNA 
Description 
POLE gene is 63.6 kb long and composed of 49 
coding exons, where the first and last one also have 
a UTR region. 
Transcription 
The length of the transcript is 7840 bp and results in 
a protein of 2286 residues. 
Protein 
Description 
The POLE gene encodes for one of the four subunits 
that form Polε (DNA polymerase epsilon) together 
with POLE2, POLE3 and POLE4 genes. This 
protein is one of the main DNA replicases in 
eukaryotes and is responsible of the replication of the 
leading strand. POLE contains both the catalytic 
active site and the proofreading exonuclease domain 
(residues 223-517). Accordingly, the POLE gene 
confers to Polε both replicative and 3' to 5' repair 
capabilities for the new strand. 
Expression 
Broadly expressed. 
Localisation 
Nuclear. 
Function 
Polε is responsible of the polymerization of the 
leading strand during DNA replication in yeast and 
humans. It also possesses 3' to 5' exonuclease 
capability to repair missincorporated nucleotides 
during DNA replication. Polε is also involved in 
DNA repair pathways such as mismatch repair 
(MMR), base excision repair (BER), nucleotide 
excision repair (NER) or double-strand break repair. 
Mutations 
Germinal 
A few missense germline mutations in the 
proofreading domain of POLE have been shown to 
be pathogenic such as W347C, N363K, D368V, 
L424V, P436S or Y458F. These are quite rare in the 
population although for unclear reasons they are 
more common than similar germline mutations in the 
polymerase gene POLD1. These mutations affect the 
exonuclease repair of Polε hence resulting in a 
mutation rate increase of about 100-fold. 
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Accordingly, these tumours are usually called 
ultramutated. 
Somatic 
Pathogenic somatic mutations in the proofreading 
domain of POLE have been found in some tumour 
types at moderate or rare frequencies. Some 
mutations in the polymerase domain have been 
suggested to be drivers but further research is 
required to validate these results. 
Implicated in 
Different human sporadic cancers 
Somatic pathogenic mutations in the proofreading 
domain of POLE have been found in 8% of 
endometrial tumours and at lower frequencies in 
other tumour types such as colorectal, glioblastoma, 
ovary, prostate, breast or gastric cancer. These 
mutations seem to confer similar phenotypes 
regardless of the tumour tissue type. These are 
missense, heterozygous mutations where no second 
hit by either mutation or LOH seem to be required, 
and they are very early events, possibly initiating. 
Some mutations are hotspots such as P286R, S297F, 
V411L or S459F but other rarer mutations have also 
been identified (eg P286H/L, S297Y, F367S, 
L424V/I, P436R, M444K, A456P). These mutations 
affect the proofreading of the protein resulting in 
ultramutation with an overrepresentation of C>A. 
More specifically, POLE tumours have mutational 
signature 10 as reported by Alexandrov et al, with 
extremely prominent TCG>TTG and TCT>TAT 
substitutions and transcriptional strand bias. As a 
result, there is an overrepresentation of some specific 
missense mutations and nonsense mutations. In 
addition, it may explain why some cancer driver 
genes in POLE tumours tend to show mutations 
otherwise relatively uncommon such as R213X in 
TP53 or R88Q in PIK3CA. POLE tumours are 
hardly ever concomitant with microsatellite 
instability, although a few tumours with both 
phenotypes have been described, and do not seem to 
show chromosomal instability as their karyotype is 
nearly diploid. 
Disease 
Patients with somatic POLE driver mutations are 
younger on average, although they have a broad 
range of ages. For colorectal cancer, most mutations 
are right-sided so they are relatively rare in rectal 
cancer. 
Prognosis 
POLE tumours in endometrial cancer, colorectal 
cancer and glioblastoma show excellent prognosis in 
early disease. Similar patterns are expected in any 
other tumour type although it is not formally proven 
due to the low frequency of these mutations. Such 
good prognosis is because of very high 
immunogenicity with upregulation of immune 
checkpoint and other immunosuppressive genes. 
Accordingly, POLE proofreading pathogenic 
mutation is also a promising candidate biomarker for 
checkpoint blockade immunotherapy. They may also 
be sensitive to treatment with nucleoside analogs as 
they increase the mutation burden to a level where 
tumour cells are not viable. 
Proofreading-associated polyposis 
(PPAP) 
Disease 
Autosomal dominant disease with high risk for 
endometrial and/or colorectal adenoma or carcinoma 
due to germline mutations in POLE or POLD1 
genes. 
Prognosis 
Probably good prognosis in early disease as found 
with POLE somatic mutations, although not 
formally proven. Similarly, these patients are likely 
to respond to checkpoint blockade immunotherapy. 
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